RCKT Stock Surges More Than 10% in Premarket Trading Following FDA Approval of Its First Gene Therapy for Rare Pediatric Immune Disorder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 27 2026
0mins
Source: stocktwits
FDA Approval: The FDA has approved Rocket Pharmaceuticals' gene therapy, Kresladi, as the first commercial product targeting children with severe Leukocyte Adhesion Deficiency Type I (LAD-I), a rare genetic immune disorder.
Market Impact: Following the approval, shares of Rocket Pharmaceuticals surged by 11% in pre-market trading, reflecting strong investor sentiment and increased trading volume.
Treatment Mechanism: Kresladi utilizes the patient's own blood stem cells, genetically modified to carry functional copies of the ITGB2 gene, which are then infused back into the body to improve immune function.
Future Plans: Rocket Pharmaceuticals is expanding its pipeline beyond LAD-I, with plans for studies targeting additional conditions, including dilated cardiomyopathy, and aims to confirm long-term clinical benefits of Kresladi through follow-up studies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RCKT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RCKT
Wall Street analysts forecast RCKT stock price to rise
11 Analyst Rating
6 Buy
4 Hold
1 Sell
Moderate Buy
Current: 3.160
Low
5.00
Averages
8.63
High
16.00
Current: 3.160
Low
5.00
Averages
8.63
High
16.00
About RCKT
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rocket Pharmaceuticals Completes PRV Sale, Cash Increases to $320M
- Cash Flow Enhancement: Rocket Pharmaceuticals disclosed that after completing the sale of its rare pediatric disease priority review voucher (PRV), its cash, cash equivalents, and investments exceeded $320 million, significantly up from $144.4 million as of March 31, indicating a substantial improvement in the company's financial position.
- Financing Context: The company announced in April that it expected to generate $180 million in potential gross proceeds from the PRV sale, which was awarded following FDA approval of its gene therapy Kresladi, reflecting the market recognition of its product.
- Use of Funds: The non-dilutive capital from this transaction will extend Rocket Pharmaceuticals' cash runway through Q2 2028, ensuring the sustainability of its operations and R&D activities in the coming years.
- Market Outlook: While Kresladi's FDA approval validates the company's platform, market analysis indicates that its commercial upside remains limited, necessitating attention on how the company will leverage the new funds to drive product commercialization.
See More
Rocket Pharmaceuticals Sells PRV for $180 Million
- Successful PRV Sale: Rocket Pharmaceuticals has successfully closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $180 million, significantly enhancing the company's financial position with this non-dilutive revenue.
- Cash Flow Improvement: Prior to the PRV sale, Rocket had cash and cash equivalents of $144.4 million, and post-sale, the total cash and investments are expected to rise to approximately $322.6 million, which will fund operations into the second quarter of 2028, ensuring continuity in R&D and marketing efforts.
- Strategic Implications: The sale of the PRV not only provides financial support but also strengthens Rocket's competitive edge in the gene therapy market for rare diseases, particularly in its clinical-stage cardiovascular programs.
- Future Outlook: Rocket's gene therapy platform targets various cardiovascular diseases, which is expected to attract more investor interest and further drive its expansion and technological innovation in the global market.
See More
Rocket Pharmaceuticals to Attend Global Healthcare Conferences
- Conference Participation: Rocket Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, with CEO Gaurav Shah engaging in a fireside chat and hosting investor meetings, highlighting the company's active presence and influence in the healthcare sector.
- Gene Therapy Pipeline: The company focuses on gene therapies for rare diseases, particularly cardiovascular conditions, with three clinical-stage programs targeting major inherited cardiomyopathy subtypes affecting over 100,000 patients in the U.S. and EU, showcasing its robust capabilities in the biotechnology field.
- Technological Edge: Rocket's proprietary AAV manufacturing capabilities and years of efficacy and safety data in cardiac gene therapy enhance its competitiveness in clinical trials, which is expected to drive future product development and market penetration.
- Outlook and Risks: Despite market competition and R&D risks, Rocket's forward-looking statements reflect optimism regarding future funding and clinical trial outcomes, potentially offering investors long-term growth opportunities.
See More
Rocket Pharmaceuticals Q1 Report and KRESLADI Approval
- Financial Performance: Rocket Pharmaceuticals (RCKT) reported a Q1 GAAP EPS of -$0.42 for 2026, indicating ongoing challenges in profitability that may affect investor confidence moving forward.
- Cash Position: As of March 31, 2026, the company held $144.4 million in cash, cash equivalents, and investments, excluding PRV monetization, providing a financial cushion for future R&D and operational needs.
- KRESLADI Approval: The FDA's approval of KRESLADI gene therapy for Severe Leukocyte Adhesion Deficiency Type 1 validates Rocket's platform; however, the limited commercial upside may hinder future revenue growth expectations.
- Market Reaction: During the 2026 Leerink Global Healthcare Conference, Rocket discussed the KRESLADI approval, but market reactions remain cautious regarding its commercialization prospects, potentially leading to stock price volatility.
See More
Rocket Pharmaceuticals Receives Accelerated FDA Approval for Kresladi
- FDA Accelerated Approval: Rocket Pharmaceuticals' Kresladi has received accelerated FDA approval for treating Severe Leukocyte Adhesion Deficiency Type I, marking a significant milestone in the company's gene therapy efforts for rare diseases, which is expected to enhance market performance.
- Clinical Trial Success: Kresladi demonstrated a 100% overall survival rate in a global Phase 1/2 study, meeting all primary and secondary endpoints without serious treatment-related adverse events, further boosting investor confidence in its efficacy.
- Significant Financial Impact: The Rare Pediatric Disease Priority Review Voucher (PRV) awarded is projected to add approximately $200 million in non-dilutive funding, significantly improving the company's financial position and extending its runway into 2028, despite a nearly 27% decline in stock price post-FDA approval.
- Analyst Outlook Positive: Wedbush analyst reiterated an Outperform rating for Rocket, suggesting that Kresladi's approval will mitigate payer pushback, and although pricing remains undisclosed, the management's strong execution is likely to drive future growth.
See More
Rocket Pharmaceuticals Secures FDA Approval for KRESLADI
- FDA Approval Milestone: On March 27, Rocket Pharmaceuticals announced that the FDA approved its first marketed product, KRESLADI, for a rare pediatric disorder, marking a significant commercial foothold in the ultra-rare disease market with strategic implications for future growth.
- First Gene Therapy: KRESLADI is the first FDA-approved gene therapy for this condition, further solidifying Rocket's leadership position in the biotechnology sector and laying the groundwork for future product development.
- Priority Review Voucher: The company received a Rare Pediatric Disease Priority Review Voucher, an asset that biotech firms can monetize, with management evaluating strategic options for the voucher to enhance financial flexibility, indicating proactive financial planning for future endeavors.
- Measured Commercial Launch: Rocket plans a limited rollout of KRESLADI through specialized centers, and despite the challenges posed by a small patient population, the company reported $188.9 million in cash and investments as of December 31, 2025, ensuring operational sustainability.
See More
Rocket Pharmaceuticals Completes PRV Sale, Cash Increases to $320M
- Cash Flow Enhancement: Rocket Pharmaceuticals disclosed that after completing the sale of its rare pediatric disease priority review voucher (PRV), its cash, cash equivalents, and investments exceeded $320 million, significantly up from $144.4 million as of March 31, indicating a substantial improvement in the company's financial position.
- Financing Context: The company announced in April that it expected to generate $180 million in potential gross proceeds from the PRV sale, which was awarded following FDA approval of its gene therapy Kresladi, reflecting the market recognition of its product.
- Use of Funds: The non-dilutive capital from this transaction will extend Rocket Pharmaceuticals' cash runway through Q2 2028, ensuring the sustainability of its operations and R&D activities in the coming years.
- Market Outlook: While Kresladi's FDA approval validates the company's platform, market analysis indicates that its commercial upside remains limited, necessitating attention on how the company will leverage the new funds to drive product commercialization.
See More
Rocket Pharmaceuticals Sells PRV for $180 Million
- Successful PRV Sale: Rocket Pharmaceuticals has successfully closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $180 million, significantly enhancing the company's financial position with this non-dilutive revenue.
- Cash Flow Improvement: Prior to the PRV sale, Rocket had cash and cash equivalents of $144.4 million, and post-sale, the total cash and investments are expected to rise to approximately $322.6 million, which will fund operations into the second quarter of 2028, ensuring continuity in R&D and marketing efforts.
- Strategic Implications: The sale of the PRV not only provides financial support but also strengthens Rocket's competitive edge in the gene therapy market for rare diseases, particularly in its clinical-stage cardiovascular programs.
- Future Outlook: Rocket's gene therapy platform targets various cardiovascular diseases, which is expected to attract more investor interest and further drive its expansion and technological innovation in the global market.
See More
Rocket Pharmaceuticals to Attend Global Healthcare Conferences
- Conference Participation: Rocket Pharmaceuticals will participate in the Jefferies Global Healthcare Conference on June 4 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, with CEO Gaurav Shah engaging in a fireside chat and hosting investor meetings, highlighting the company's active presence and influence in the healthcare sector.
- Gene Therapy Pipeline: The company focuses on gene therapies for rare diseases, particularly cardiovascular conditions, with three clinical-stage programs targeting major inherited cardiomyopathy subtypes affecting over 100,000 patients in the U.S. and EU, showcasing its robust capabilities in the biotechnology field.
- Technological Edge: Rocket's proprietary AAV manufacturing capabilities and years of efficacy and safety data in cardiac gene therapy enhance its competitiveness in clinical trials, which is expected to drive future product development and market penetration.
- Outlook and Risks: Despite market competition and R&D risks, Rocket's forward-looking statements reflect optimism regarding future funding and clinical trial outcomes, potentially offering investors long-term growth opportunities.
See More
Rocket Pharmaceuticals Q1 Report and KRESLADI Approval
- Financial Performance: Rocket Pharmaceuticals (RCKT) reported a Q1 GAAP EPS of -$0.42 for 2026, indicating ongoing challenges in profitability that may affect investor confidence moving forward.
- Cash Position: As of March 31, 2026, the company held $144.4 million in cash, cash equivalents, and investments, excluding PRV monetization, providing a financial cushion for future R&D and operational needs.
- KRESLADI Approval: The FDA's approval of KRESLADI gene therapy for Severe Leukocyte Adhesion Deficiency Type 1 validates Rocket's platform; however, the limited commercial upside may hinder future revenue growth expectations.
- Market Reaction: During the 2026 Leerink Global Healthcare Conference, Rocket discussed the KRESLADI approval, but market reactions remain cautious regarding its commercialization prospects, potentially leading to stock price volatility.
See More
Rocket Pharmaceuticals Receives Accelerated FDA Approval for Kresladi
- FDA Accelerated Approval: Rocket Pharmaceuticals' Kresladi has received accelerated FDA approval for treating Severe Leukocyte Adhesion Deficiency Type I, marking a significant milestone in the company's gene therapy efforts for rare diseases, which is expected to enhance market performance.
- Clinical Trial Success: Kresladi demonstrated a 100% overall survival rate in a global Phase 1/2 study, meeting all primary and secondary endpoints without serious treatment-related adverse events, further boosting investor confidence in its efficacy.
- Significant Financial Impact: The Rare Pediatric Disease Priority Review Voucher (PRV) awarded is projected to add approximately $200 million in non-dilutive funding, significantly improving the company's financial position and extending its runway into 2028, despite a nearly 27% decline in stock price post-FDA approval.
- Analyst Outlook Positive: Wedbush analyst reiterated an Outperform rating for Rocket, suggesting that Kresladi's approval will mitigate payer pushback, and although pricing remains undisclosed, the management's strong execution is likely to drive future growth.
See More
Rocket Pharmaceuticals Secures FDA Approval for KRESLADI
- FDA Approval Milestone: On March 27, Rocket Pharmaceuticals announced that the FDA approved its first marketed product, KRESLADI, for a rare pediatric disorder, marking a significant commercial foothold in the ultra-rare disease market with strategic implications for future growth.
- First Gene Therapy: KRESLADI is the first FDA-approved gene therapy for this condition, further solidifying Rocket's leadership position in the biotechnology sector and laying the groundwork for future product development.
- Priority Review Voucher: The company received a Rare Pediatric Disease Priority Review Voucher, an asset that biotech firms can monetize, with management evaluating strategic options for the voucher to enhance financial flexibility, indicating proactive financial planning for future endeavors.
- Measured Commercial Launch: Rocket plans a limited rollout of KRESLADI through specialized centers, and despite the challenges posed by a small patient population, the company reported $188.9 million in cash and investments as of December 31, 2025, ensuring operational sustainability.
See More
